Results 81 to 90 of about 27,891 (313)

Proteomic changes upon treatment with semaglutide in individuals with obesity

Nature Medicine
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in ...
Lasse Maretty, D. Gill, L. Simonsen, Keng C. Soh, L. Zagkos, Michael Galanakis, J. Sibbesen, Miquel Triana Iglesias, Anna Secher, Dirk Valkenborg, Jonathan Q. Purnell, L. Knudsen, Abd A. Tahrani, Milan Geybels   +13 more
semanticscholar   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction?:Or A Drug Class Worth Reviving? [PDF]

, 2019
The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective ...
Janbon M, Loubatieres A, Mailhot J, Rados DV, The University Group Diabetes Program   +4 more
core   +2 more sources

Microtopography enhances intestinal drug absorption via Piezo1‐mediated tight junction modulation

BMEMat, EarlyView.
Microtopography‐driven enhancement of oral peptide drug delivery by activating Piezo1 channels significantly improves paracellular permeability and bioavailability, offering a novel approach for optimizing macromolecule absorption in pharmaceutical formulations.
Yu Hu, Nan Xu, Xin Li, Xiaowo Kang, Tieyuan Bian, Junsheng Lin, Hao Tang, Yinyin Bao, Lu Zhang, Hongyan Yuan, Mingxi Yao, Xingyu Jiang, Zhi Luo   +12 more
wiley   +1 more source

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Nature Medicine
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes.
D. Ryan, I. Lingvay, J. Deanfield, S. Kahn, Eric Barros, B. Burguera, H. Colhoun, Cintia Cercato, D. Dicker, D. B. Horn, G. Hovingh, O. Jeppesen, A. Kokkinos, A. M. Lincoff, S. Meyhöfer, Tugce K Oral, Jorge Plutzky, A. V. van Beek, J. P. Wilding, Robert F Kushner   +19 more
semanticscholar   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Deleting death and dialysis: Conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD) [PDF]

, 2018
The uremic syndrome, which is the clinical expression of chronic kidney disease (CKD), is a complex amalgam of accelerated aging and organ dysfunctions, whereby cardio-vascular disease plays a capital role. In this narrative review, we offer a summary of
Castillo-Rodriguez, Esmeralda, Glorieux, Griet, Ortiz, Alberto, Van Laecke, Steven, Vanholder, Raymond, Verbeke, Francis   +5 more
core   +4 more sources

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source

Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

Physiological Reports, 2023
Metabolic functions of GLP‐1 and its analogues have been extensively investigated. In addition to acting as an incretin and reducing body weight, we and others have suggested the existence of GLP‐1/fibroblast growth factor 21 (FGF21) axis in which liver ...
Jia Nuo Feng, Weijuan Shao, Tianru Jin
doaj   +1 more source

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

Frontiers in Pharmacology
Diabetes mellitus is a global disease in which alterations in the internal environment disrupt the bone-fat balance, contributing to osteoporosis. Semaglutide, a single-target, long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been ...
Yawei Tian, Huiming Liu, Xiaoxue Bao, Yukun Li   +3 more
doaj   +1 more source